Randomized trial: Ultra-hypofractionated vs. conventionally fractionated radiotherapy for prostate cancer
19 Jan, 2021 | 01:14h | UTCUltra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)